Rheumatology Network's Top 5: July 2, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 2, 2021.
FDA Updates PDUFA Date for Upadacitinib for Patients With Psoriatic Arthritis and Ankylosing Spondylitis
The US Food and Drug Administration (FDA) has delayed its decision on upadacitinib (RINVOQ) for the for the treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis.
Click the image to view the story.
Andrew L Concoff, MD, FACR, CAQSM: Value-Based Care
Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Click the image to view the story.
Rheumatoid Arthritis Quiz Roundup
Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.
Click the image to view the story.
Lupus: Will This Butterfly Soon Take Flight?
Eric Morand, MD, PhD, explains why rheumatologists failing in lupus while succeeding so spectacularly in diseases like rheumatoid arthritis and what needs to change.
Click the image to view the story.
Serum Protein Biomarker Panel Differentiates Between Psoriatic Arthritis and Rheumatoid Arthritis
In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.
Click the image to view the story.
